196 related articles for article (PubMed ID: 38151479)
1. Improvement of severe alopecia areata in an adolescent patient on upadacitinib.
Ha GU; Kim JH; Jang YH
Pediatr Dermatol; 2024; 41(2):356-358. PubMed ID: 38151479
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
3. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
Stefanis AJ
Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
[TBL] [Abstract][Full Text] [Related]
4. Upadacitinib for moderate to severe atopic dermatitis.
Navarro-Triviño F; Alcantara-Luna S; Domínguez-Cruz J; Galán-Gutiérrez M; Ruiz-Villaverde R; Pereyra-Rodriguez JJ; Armario-Hita JC
Immunotherapy; 2023 Aug; 15(11):799-808. PubMed ID: 37194577
[TBL] [Abstract][Full Text] [Related]
5. Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata.
Kołcz K; Żychowska M; Sawińska E; Reich A
Dermatol Ther (Heidelb); 2023 Mar; 13(3):843-856. PubMed ID: 36639612
[TBL] [Abstract][Full Text] [Related]
6. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
9. JAK Inhibitors for Treatment of Alopecia Areata.
Wang EHC; Sallee BN; Tejeda CI; Christiano AM
J Invest Dermatol; 2018 Sep; 138(9):1911-1916. PubMed ID: 30057345
[TBL] [Abstract][Full Text] [Related]
10. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
12. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
13. Upadacitinib: Mechanism of action, clinical, and translational science.
Mohamed MF; Bhatnagar S; Parmentier JM; Nakasato P; Wung P
Clin Transl Sci; 2024 Jan; 17(1):e13688. PubMed ID: 37984057
[TBL] [Abstract][Full Text] [Related]
14. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
[TBL] [Abstract][Full Text] [Related]
15. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
Ramot Y; Zlotogorski A
Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib for the Treatment of Alopecia Areata.
Freitas E; Guttman-Yassky E; Torres T
Drugs; 2023 Jun; 83(9):761-770. PubMed ID: 37195491
[TBL] [Abstract][Full Text] [Related]
17. JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
[TBL] [Abstract][Full Text] [Related]
18. A review of upadacitinib in rheumatoid arthritis.
Tanaka Y
Mod Rheumatol; 2020 Sep; 30(5):779-787. PubMed ID: 32530345
[TBL] [Abstract][Full Text] [Related]
19. Dual Efficacy of Upadacitinib in 2 Patients With Concomitant Severe Atopic Dermatitis and Alopecia Areata.
Gambardella A; Licata G; Calabrese G; De Rosa A; Alfano R; Argenziano G
Dermatitis; 2021 Oct; 32(1S):e85-e86. PubMed ID: 34405831
[No Abstract] [Full Text] [Related]
20. Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study.
Flora A; Kozera E; Frew JW
J Am Acad Dermatol; 2023 Jul; 89(1):137-138. PubMed ID: 36806643
[No Abstract] [Full Text] [Related]
[Next] [New Search]
